Chandan Healthcare reappoints auditors for FY27
Chandan Healthcare Limited reappointed M/s. Renu Agrawal & Co. as statutory auditor and M/s. Rahul Jain & Associates as cost auditor for FY27. The decisions were made in a board meeting on May 29, 2026. Both firms will serve a one-year term.

*this image is generated using AI for illustrative purposes only.
Chandan Healthcare Limited has reappointed its statutory and cost auditors for the financial year 2026-27 during a board meeting held on May 29, 2026. The Board approved the reappointment of M/s. Renu Agrawal & Co. as the statutory auditor and M/s. Rahul Jain & Associates as the cost auditor, each for a term of one year.
Statutory Auditor Details
M/s. Renu Agrawal & Co., a firm of Chartered Accountants holding FRN No. 018547C, has been reappointed to serve as the statutory auditor. The firm, located at Unit No. 302, Vipul Trade Centre, Sector 48, Sohna Road, Gurgaon-122018, offers services in audit and assurance, tax and regulatory, transaction advisory, and consulting.
Cost Auditor Details
The Board also reappointed M/s. Rahul Jain & Associates as the cost auditor for FY27. The firm, with FRN No. 101515, is a partnership firm of Cost Accountants based at 606, Signature Global Mall Vaishali Sector-3, Ghaziabad, UP – 201010. It specializes in Cost Audit, Costing Systems, and Cost Study and analysis.
| Auditor Firm | Type | Term | FRN No. |
|---|---|---|---|
| M/s. Renu Agrawal & Co. | Statutory Auditor | 1 Year | 018547C |
| M/s. Rahul Jain & Associates | Cost Auditor | 1 Year | 101515 |
Historical Stock Returns for Chandan Healthcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -6.02% | -2.24% | -10.47% | -31.35% | +23.29% | +31.93% |
What factors might influence the Board's decision to extend the auditors' tenure beyond the current one-year term?
How will the reappointment of these auditors impact Chandan Healthcare's compliance and financial reporting strategies in the upcoming fiscal year?
Could the reappointment signal any upcoming changes in the company's financial structure or regulatory focus?

































